Abstract 5921
Background
Afatinib (AFA), an irreversible ErbB family blocker, is used at the standard starting dose of 40mg for the treatment of patients with EGFR M+ NSCLC. It has been shown previously tolerability guided dose reduction effectively decreases incidence and severity of treatment related adverse events (AEs) during the treatment, and that treatment-related dose reduction was more likely in patients who had higher plasma concentrations of AFA before dose adaptation (Yang et al., Annals of Oncology 2016). After dose reduction, concentrations were similar to those obtained in patients who did not experience AEs, with comparable efficacy. We thus intended to determine a threshold concentration related with dose-reduction or AEs leading to dose-reduction (AELDR).
Methods
Patients (N = 390) with AFA treatment, analyzable trough plasma concentration (Cmin) determination at D22 and follow-up of at least 6 months were identified from LUX-Lung (LL3 & LL6) studies. Receiver operating characteristic (ROC) curve analysis (univariable regression model) was performed to assess a discrimination potential of AFA Cmin for AELDR.
Results
The most discriminating threshold of AFA Cmin associated with dose reduction or AELDR between D22 sampling and M6 is at 34 ng/ml. With this concentration threshold, there is a maximal AUC of 0.63 (95%CI: [0.58 – 0.69], a maximal Younden index of 0.267 (49% sensitivity, 78% specificity), with an odds ratio of 3.37 [2.10 – 5.40]) indicating that dose reduction or AELDR are more frequent in patients with concentration ≥34 ng/mL. The analysis also showed that concentration is more often elevated in female, older (>65y), eastern Asian and low-body weight patients.
Conclusions
Monitoring of AFA plasma levels might be useful for the management of AEs in patients with NSCLC, especially for patients having factors known to be associated with higher AFA plasma exposure or toxicities. These results support the approach of adapting treatment dose based on plasma concentrations of AFA both forAEs and efficacy.
Clinical trial identification
NCT01121393, NCT00949650.
Editorial acknowledgement
Legal entity responsible for the study
M. Molimard.
Funding
Boehringer Ingelheim.
Disclosure
C. Frohn: Full / Part-time employment: Boehringer Ingelheim International GmbH. C. Maritaz: Full / Part-time employment: Boehringer Ingelheim France. All other authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract